Figure 2. Prognostic Information of the On-Treatment Modified Glasgow Prognostic Score (mGPS) in the Disease Control (DC) Subgroup of the Phase 3 IMmotion151 Trial.

Progressive disease (PD) in the first staging according to the Response Evaluation Criteria in Solid Tumors assessed by the Independent Review Committee (IRC-RECIST) is associated with unfavorable overall survival (OS), whereas outcomes in the complete or partial remission (CR/PR) and stable disease (SD) subgroups differs only slightly. The on-treatment mGPS at first staging has a strong prognostic value, even in the DC subgroup (ie, patients with CR/PR or SD) and identifies a high-risk group of patients (mGPS 2) in the DC subgroup.